nope...in today release says it will be second Q
Athersys expects initial results from the study to be disclosed in the second quarter of 2014.
sell yourself to psycho house. Mesoblast have heart attack, disc repair, etc. Nothing from ATHX pipeline. You will do better to go on NBS forum or write email to Discgenics. I hope you own mesoblast because this two companies will rip into their revenue in future.
that will be 36% dilution. MC is now 42M, when you add 36% that would be a 57M MC. That is pretty good in my opinion, nothing dramatic.
Now count with r/s 10 for 1. That will bring the price to $6 and number of shares to JUST 9.6M. Now imagine what will happen when they uplist and have good Q. Institutions will try to get shares. The thing is there is just what will be left from 9.6M. I can't wait to see this.
and load up.
i was more shocked by Japan news. Why ATHX didn't go up to $3 at that point.
somebody will bid for patents after
they have to go way of partnership. If they try to market generic on their own, they have to spend big $$$ on sale force and traveling. It is almost impossible for small company like they are to go hospital by hospital and make sales with generic. They need experienced big partner who will do the job...like the deal with Par.
I will wait and see. In my experience just to get approved for companies like this is the easiest obstacle. The hard one is sales.
BTW IGXT Forfivo is tune up Effexor. saw that one in IPCI pipeline. That is my point. On paper everything looks great, with sales of 700M in US so you would think the IGXT is going to get some nice revenue. In reality the sales in a year were so small that they have to dilute to get money.
I know Par. They partnered IGXT also. I just wanna know how much they can get. It is common to be from 10 up to 40%. I guess it will not be 40 but even 20 would be significant. I was on their web and i did not find anything about production facility. The problem with stock like this is sales. They have great technology but i wanna see if they are able to sell it. If i wait for that the train will leave. I havelimited funds and many comlanies on radar.
Good example of bad marketing is ARNA with Belviq and IGXT with Forfivo. This stocks would trade 10x higher otherwise.
Also with generic in pipeline...are they able to manufacture them or they have to use someone else?
Last one if anyone knows. Do they have strong marketing in US? Some partner or something? I saw not many, but some (not that many starter pharma with new tech around) good new tech pharma being destroyed just because they coudn't sell what they have.
before i decided to sell. Now i got interested again because of price.
Anyway i'm asking opinion from long term holders for i was out of IGXT for over 6 months.
I was reading 10k from Nov and i concluded it is a big mess. How is this situation with Sublingual Film Product ?
When i sold it was just litigation with Reckitt Benckiser. Now there is a second problem with Actavis. They have there own version of this film and they geting the same treatment from Reckitt. Do i understand that
Forfivo sells bad and my hopes for that product are gone so i would buy in just on new one. What do you guys think about close future?
MM's flippers don't care about this things. They care about buying low...as i do. Why not to use them in your advance?